Takeda is facing major revenue challenges from US generics to its big seller Velcade, but is looking to successor and other new products to more than plug the gap.

The takeover battle for India’s Fortis Healthcare has accelerated, with Manipal Healthcare, backed by US investment management firm TPG Capital, raising its offer for the troubled hospital chain against the backdrop of a messy dispute over the bidding process. Malaysian suitor IHH Healthcare has also since extended its offer validity period.

Open Innovation and global partnering are becoming one of the most frequent themes of bio conferences in South Korea and elsewhere. Scrip talked to global experts at the recent Bio Korea 2018 meeting about their views on the current climate and trends for open innovation in Asia, as well as some challenges and benefits in pursuing open innovation approaches with Asian companies.

Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.

Pharming Group, a company that has been on the drug development scene since the ‘80s, has recorded a quarterly net profit for the first time – two years earlier than previously forecast.

President Trump's much anticipated pronouncements on drug pricing reform leave a lot to be clarified. Biopharma companies and their leaders should grasp the opportunity to lead from the front and propose tangible and transformative actions that deliver benefits for all stakeholders, writes Viren Mehta, founding partner of Mehta Partners LLC.

DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.

Many of US drug pricing blueprint's proposals could be accomplished administratively, but will still be shaped by stakeholder feedback.

The company says a subgroup of lung cancer patients with high pre-treatment monocyte levels showed promising response and PFS rates in study pairing Syndax’s selective HDAC inhibitor with Merck’s Keytruda. Mature data will inform future Phase III melanoma plans.

Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.

The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET.